Page 143 - Eceptor News Today

Researchers evaluate antiviral effects of CD63 tetraspanin extracellular vesicles against SARS-CoV-2 and HIV-1.

Researchers reported a new monoclonal antibody, P2G3, which significantly neutralized the SARS-CoV-2 Omicron variant.

Researchers investigated how monoclonal antibodies, S309 and AZD7442, reduced lung infection in mice infected with the SARS-CoV-2 new variant of concern Omicron's BA.1, BA.1.1, and BA.2 sublineages.

In a new study, researchers discovered human monoclonal antibodies, which were specific and potent against the severe acute respiratory syndrome coronavirus 2 Omicron variant.

Researchers conducted an umbrella review and meta-analysis of the RAAS inhibitors' impact on COVID-19 clinical outcomes.

Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, achieved a high rate of complete response in patients with high-risk large B-cell lymphoma (LBCL).

A recent study posted to the bioRxiv* preprint server demonstrated the neutralizing capacity of existing SARS-CoV-2 vaccines against the severe acute respiratory coronavirus 2 (SARS-CoV-2) Omicron BA.2 and BA.1 sublineages.

Researchers demonstrate the broad neutralization potential of a strategically engineered circRNA using mice as a model system.

A recent study posted to the medRxiv* preprint server evaluated the antibody responses against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) patients receiving hemodialysis.

A recent study posted to the bioRxiv* preprint server evaluated the effects of the waning of antibodies after coronavirus disease 2019 (COVID-19) infection or vaccination.